Euro-area private credit is expanding as households and companies borrow more, which points to easier financial conditions and a friendlier backdrop for growth focused businesses. That puts a spotlight on healthy high growth potential stocks where analysts already expect strong earnings momentum and solid balance sheets. This article breaks down three picks from the screener so you can see how they fit this theme and decide which deserve a closer look.

The stocks covered below are just a small sample of this theme. The full screen surfaces 288 more companies that analysts also expect to have strong earnings momentum and acceptable financial positions. To identify and analyze the ideas that best fit your own criteria, head straight to the Healthy high growth potential screener.

Amylyx Pharmaceuticals (AMLX)

Overview: Amylyx Pharmaceuticals is a clinical stage biotech company focused on developing treatments for neurodegenerative diseases and rare endocrine conditions, led by its late stage programs Avexitide for post bariatric hypoglycemia and AMX0114/AMX0035 for disorders such as progressive supranuclear palsy and Wolfram syndrome. The core appeal for growth focused investors is that these programs target areas with high unmet medical need, where successful approvals could turn today’s pipeline into tomorrow’s earnings.

Market Cap: US$4.65b

Amylyx Pharmaceuticals gives you exposure to a pure play growth story built around late stage drug candidates that sit at the heart of the Healthy high growth potential theme. Avexitide and its broader GLP 1 antagonist franchise aim to create the company’s first meaningful revenue stream in diseases that currently lack approved therapies. Recent LUCIDITY Phase 3 data in post bariatric hypoglycemia and plans for an NDA by the end of 2026 show how close that earnings inflection could be. However, revenue today is effectively zero and the company still reports sizeable losses funded by a US$317 million cash balance and fresh equity. Execution risk around regulatory decisions, commercialization and potential dilution remains high. Investors who can tolerate clinical volatility may want to look closer at how this pipeline could reshape Amylyx’s financial profile over the next few years.

Amylyx Pharmaceuticals could be on the verge of turning late stage science into a real business, yet the biggest clue may be hiding in how its balance sheet and cash runway intersect with the Amylyx Pharmaceuticals financial health report

Oracle (ORCL)

Overview: Oracle is a global enterprise software and cloud company that runs critical databases and business applications for governments, large corporates and institutions, with its Fusion Cloud and NetSuite platforms at the center of its push into subscription based cloud ERP, HR, finance and industry specific systems. The strongest tie to the Healthy high growth potential theme is Oracle’s cloud applications and Oracle Cloud Infrastructure businesses, where analysts link expected multi year earnings growth to recurring software and infrastructure contracts rather than one off licenses.

Operations: Oracle generates most of its revenue from Cloud and software at about US$58.5b, with smaller contributions from Services at about US$5.7b and Hardware at about US$3.1b.

Market Cap: US$417b

Oracle is worth a closer look if you want exposure to large scale cloud earnings growth that is already flowing through the numbers. Analysts expect earnings and revenue to grow at roughly mid 20% rates over the next 3 years, helped by recurring cloud subscriptions, a very large AI related contract backlog and Oracle’s position as a key infrastructure partner for workloads like OpenAI. The P/E sits below many software peers and some valuation models point to a wide gap between price and estimated cash flow value, yet the company carries high debt and plans further funding for its data center buildout. That mix of high growth potential and balance sheet risk makes Oracle a high conviction idea for some investors and a company others will watch from the sidelines.

Oracle’s cloud growth story and AI workload demand may be only half the picture. The real surprise could be how expectations stack up against the analyst forecasts for Oracle and what that implies for the next leg of this story.

Palantir Technologies (PLTR)

Overview: Palantir Technologies builds software platforms like Gotham, Foundry, Apollo and its Artificial Intelligence Platform that help governments and large companies bring together vast amounts of data, run advanced analytics and deploy AI tools into day to day operations. The strongest link to the Healthy high growth potential theme comes from Palantir Foundry and its AI and large language model capabilities, which are being used by commercial customers to create new revenue streams and efficiency gains rather than relying solely on legacy government contracts.

Operations: Palantir generates slightly more revenue from Government customers at about US$3.2b than from Commercial customers at about US$2.9b, with the United States contributing the majority of overall revenue at about US$4.8b.

Market Cap: US$426.4b

Palantir Technologies is worth a close look if you want exposure to a high growth data and AI platform that is already profitable. Earnings and revenue are both forecast to grow at about 32% a year, backed by strong net margins near 49% and return on equity above 30%, which fits squarely with the Healthy high growth potential screen. Government programs like the Maven System help support multi year visibility, while US commercial demand for Foundry and the AI Platform is becoming an important second engine. The main catch is valuation, with premium multiples that could compress if growth cools or funding conditions tighten. Investors who are comfortable with price volatility may want to study whether that growth profile justifies the premium.

Palantir Technologies already has scale, profitability and a premium price tag that many investors debate. The missing piece is how that growth profile lines up with the analyst forecasts for Palantir Technologies and what could shift that balance next.

Curious To Explore Powerful Alternatives?

Fresh stock ideas do not stay under the radar for long. Screens are already picking up early breakout momentum that others may miss. Scan these while it matters and consider your options promptly.

• Spot companies building the backbone of AI and data centers before the story goes mainstream by running the 55 AI infrastructure stocks.
• Track potential yield opportunities that could help keep your portfolio income growing while prices are still catching up with fundamentals through the 11 dividend fortresses.
• Look for early movers in robotics and factory automation while they are still dropping clues in earnings rather than headlines using the curated 38 robotics and automation stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.